Drug recall · March 6, 2013
EXPAREL recall
Why: Subpotent; bupivacaine
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA
- Lots / codes
Lot #11-2005 Control #23542 Manufacture Date: 05Dec11 2011-L-009
- Quantity
- 324 vials
- Company
- Pacira Pharmaceuticals, Inc., San Diego, CA
- Distribution
- Nationwide distribution: AZ, DC, FL, GA, MA, NJ, NY, OH, and TX.
- Initiated
- December 17, 2012 · Voluntary: Firm initiated
- Classified
- February 25, 2013
- Reported
- March 6, 2013
- Ended
- May 3, 2013
- How notified
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupivacaine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.